Retrospective analysis of RNA from the OUTREACH clinical trial of patients with HCC demonstrated a non-significant trend between increased CEBPA expression post MTL-CEBPA and clinical outcome (Figure 4A). The gene discussed is CEBPA; the disease is hepatocellular carcinoma.